Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of benralizumab on airway structure/function in severe eosinophilic asthma.

Respiratory research·2026
Same author

High Systemic Corticosteroids Burden Among Moderate-to-Severe Asthma Patients in the United States.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation.

The journal of allergy and clinical immunology. Global·2026
Same author

Indirect Treatment Comparison of Tezepelumab Versus Other Biologics in Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Literature Review and Network Meta-analysis.

Advances in therapy·2026
Same author

A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE Study.

The European respiratory journal·2026
Same author

Reply to Zhao et al.: Clarifying Structural - Functional Coupling by FeNO Status in VESTIGE.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Jul 12, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Biologic effectiveness increases with earlier biologic initiation after severe asthma onset.

Arjun Mohan1, Reynold A Panettieri2, Wendy C Moore3

  • 1Department of Medicine, Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich.

The Journal of Allergy and Clinical Immunology. Global
|July 11, 2026
PubMed
Summary

Starting biologic treatment sooner for severe asthma improves its effectiveness. A shorter delay from severe asthma onset to biologic initiation is linked to fewer exacerbations and better outcomes.

Keywords:
Allergistsbiologic therapyeffectivenessexacerbationslongitudinalobservationalpulmonologistsreal-worldsevere asthma

Related Experiment Videos

Last Updated: Jul 12, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

  • Pulmonology
  • Immunology
  • Clinical Medicine

Background:

  • Severe asthma can lead to irreversible airway damage through fibrosis and remodeling.
  • Chronic inflammation is a key driver of these pathological changes in the airways.

Purpose of the Study:

  • To evaluate how the time between severe asthma onset and biologic treatment initiation affects treatment effectiveness.
  • To analyze outcomes in US adults with severe asthma treated by specialists.

Main Methods:

  • The CHRONICLE observational study (NCT03373045) compared exacerbation rates before and after biologic initiation.
  • Multivariable models identified factors independently associated with exacerbation rates during treatment.

Main Results:

  • A 59% reduction in exacerbation rates was observed post-biologic initiation.
  • Shorter time to biologic treatment was independently associated with lower exacerbation rates (rate coefficient = 1.04; P < .001).
  • Black race was also associated with higher exacerbation rates (rate ratio = 2.40; P = .009).

Conclusions:

  • Earlier initiation of biologic therapy in severe asthma is associated with improved treatment effectiveness.
  • Adjusting for prior exacerbations and race, a shorter delay to treatment correlates with reduced exacerbations.